IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active...

19

Transcript of IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active...

Page 1: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the
Page 2: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

Specialty Generic Drugs

Contract Manufacturing

Contract Clinical Services

Page 3: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

UPDATE 13APR16FDA APPROVAL of TEMOZOLOMIDE• IDT’s first proprietary generic product• First in a portfolio of 24 approved US specialty generic drugs

• USD200m market opportunity• Distribution via Mayne Pharma

• Fundamental and transformational change to the IDT strategy, business and prospects

Page 4: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

www.idtaus.com.auwww.idtaus.com.au

IDT AUSTRALIA LTD (ASX.IDT)INVESTMENT PROPOSITIONThe Business:

US FDA approved generic drug portfolio

Two in-house products, one FDA approved

Growing contract drug development revenues

Growing contract drug manufacturing revenues

Growing clinical trial revenues (CMAX, Adelaide)

Approaching major revenue inflection point with impending product launches

Further pipeline expansion planned

High tech 12,000m2 facility in Melbourne, replacement value ~$75m

Specialization in high potent and difficult to manufacture drugs

IDT: We make good medicine. 4

Aggregate AddressableMarket over US$750m

Page 5: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

Transformative M&A

2014 and onwards

Drug development services revenues

Contract drug manufacture revenues

Contract clinical services revenues

Revenue Step Change viaProprietary IDT Generic 

Drug Portfolio

IDT Service Business:Provides revenues and capabilities

IDT Specialty Generics:Leverages facilities and multiplies margins

www.idtaus.com.au 5

35 YEAR HISTORY A PLATFORM FOR RAPID GROWTH

Page 6: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

IDT SPECIALTY DRUG PORTFOLIO 24 APPROVED US GENERIC DRUGS

• Purchased Dec14, now being moved into IDT facility and first batches manufactured

• Recently established partnership with ANI Pharma. (Nasdaq: ANIP) to commercialize first 18

• Addressable market of USD500m+ (Jun15 IMS*)

• In addition to an house portfolio of temozolomide (USD200m) and Thiotepa (USD80m, in development)

www.idtaus.com.au 6* Independent industry sales data

Page 7: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

IDTPORTFOLIO OVERVIEW

www.idtaus.com.au

Product Priority Manufacturer Distributor

US Priority Product Sales (USD, 2015)

Aminophylline 3 ANICarbidopa & Levodopa 1 Wellspring ANI 65.2

Ciprofloxacin 2 IDT ANI 44.5Clarithromycin 2 Wellspring ANI 16.2Dexamethasone 3 ANIDextroamphetamine 3 ANI

Diflunisal 1 Wellspring ANI 9.3Dipyridamole 3 ANIDoxazosin  1 IDT ANI 81.4Etodolac 3Etodolac ER 3Flecainide 1 IDT/Wellspring TBA 39.0Fluconazole 2 Wellspring ANI 98.2

7

Page 8: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

IDTPORTFOLIO OVERVIEW

www.idtaus.com.au

Product Priority Manufacturer Distributor

Priority US Product Sales (USD, 2015)

Leucovorin 1 IDT ANI 1.4Methoxsalen 2 IDT ANIMexiletine 1 Wellspring ANI 11.6Nefazodone 1 ANI 13.5Nortriptyline 2 Wellspring ANI 24.6Pindolol 1 Wellspring ANI 10.0Prazosin 1 Wellspring ANI 42.0Procainamide 3 CapsuleProcainamide ER3

Temozolomide 1 IDTMayne Pharma 200.0

Tetracycline 3 ANIThiotepa 1 TBA C. $80 (global)

8

Page 9: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

PORTFOLIOSNAPSHOT as at 13Apr16

www.idtaus.com.au 9

Temozolomide Development Manufactured Stability FDA ReviewMarketing Approval

Doxazosin Development Manufactured Stability

Leucovorin Development Manufactured

Pindolol Development

Thiotepa Development

Page 10: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

GLOBALLYAPPROVEDWORLD CLASS MANUFACTURING FACILITIES

www.idtaus.com.auwww.idtaus.com.au

ANTI–CANCER DRUGS HORMONES

HIGH CONTAINMENT TABS/CAPS HIGH CONTAINMENT TAB 

COATING

SENSITIZING DRUGS

CARBOHYDRATE DRUGS

10

Page 11: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

CMAXOUR CLINICAL UNIT

CMAX clinical trials facility, Adelaide

13,000 patient, well categorised database

Brand new 50 bed clinical unit located opp Royal Adelaide Hospital

Global client list with large amount of repeat business

Strong revenue growth and profitable

Delivered 500+ clinical trial programs for 60+ pharma & biotech companies from 21+ countries

www.idtaus.com.auwww.idtaus.com.au 11

Australia’s oldest, largest, most experienced clinical trials unit

Page 12: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

www.idtaus.com.auwww.idtaus.com.au

$$ MARGIN WITHIN VALUE CHAIN

Example: PROJECT TETON:

IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the VALUE as the API supplier.

Registration and supply of Generic Finished Dose Form could increase IDT’s share of the gross profit to 50-60%

BUILDINGAN IDTSPECIALITY GENERIC PORTFOLIO

IDT’s 2% API margin share

IDT

Generics margin up to 50 - 60%

REGISTRATION & SUPPLY

DISTRIBUTOR

WHOLESALER

12

Page 13: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

• Extract more profits from those products to improve our share of the value chain.

• Move to ownership of drug product portfolio

EXTRACT MORE PROFITS

• High fixed costs = operational leverage.• As a result, profits will rise faster than

revenues past breakeven point.

SELL MORE EXISTING PRODUCTS

This transaction moves IDT rapidly towards profits:• Purchased 23 approved generic drug products;• Reduced regulatory lag to get to market vs in-

house;• Reduced technical development & spend in-

house.

DEC14 ACQUISITION

GOOD MEDICINE& HIGHER RETURNS FOR IDT

• Develop & acquire more products to leverage our facilities & capabilities.

• This growth will in turn finance further acquisitions.

DEVELOP & ACQUIRE MORE PRODUCTS

www.idtaus.com.auwww.idtaus.com.au 13

Page 14: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

HIGHLIGHTSOF THE PASTYEAR

FINALIZED STRONG MANAGEMENT TEAMNew management team and strengthen board

www.idtaus.com.auwww.idtaus.com.au

BUILDING IN-HOUSE DRUG PORTFOLIOFiled first IDT ANDA for temozolomide November 13 (USD200m opportunity)Approval received April 16Temozolomide US distribution deal – milestones & profit splitThiotepa in development

GROWTH OF ORGANIC SERVICE REVENUESSignificant increases in sales pipeline, manufacturing and clinical servicesBeginning to see this flow through into significant revenue increases

NEW PURPOSE BUILT CLINICAL FACILITY FOR CMAXMoving end April

DEPLOYMENT OF GENERIC US DRUG PORTFOLIOANI Pharma and Mayne Pharma appointed to distribute in USMore manufacturing resources brought to bear on return to market

14

Page 15: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

BOARD &MANAGEMENT IN PLACE TO DELIVER

www.idtaus.com.auwww.idtaus.com.au

Dr Paul D R MacLeman (CEO & MD)

Deb Cailes (Market Access)

Jane Kelly (Clinical)

Paul Loria (Reg & Quality)

Joanna Johnson (CFO)

Dr David Sparling (Corp & Bus Dev)

Phil Wykes (Infrastructure)

MANAGEMENT TEAMGraeme Kaufman (Chairman)

Dr Paul D R MacLeman (MD)

Geoff Lord (Vice Chairman)

Dr Graeme Blackman (NED)

Hugh Burrill (NED)

Alan Fisher (NED)

Reo Shigeno (NED)

BOARD

15

Strong generics and manufacturing backgrounds

Operational and business building experience

Page 16: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

FINANCIALLYPOSITIONED TO DELIVER

MARKET CAP $73.5m (13Apr16)FINANCIALS  (ASX: IDT)

* $4.25m currently unused debt facility available

CAPITAL STRUCTURE

SHARES ON ISSUE 219.4M

UNLISTED OPTIONS 500,000

STOCK PRICE (13April16) A$0.335

AV. TRADING VOL./DAY 145,000

TOP 20 SHAREHOLDERS 61.8%

www.idtaus.com.auwww.idtaus.com.au 16

FY2014 FY2015 1H FY2016

REVENUE $13.4m $15.7m $6.5m

EARNINGS AFTER TAX ($6.6m) ($3.0m) ($3.5m)

NET ASSETS $25.5m $39.2m $43.7m

CASH $2.40 $0.13 $4.90

DEBT* $0.1m $0.0m $0.0m

Page 17: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

TARGET2016 MILESTONES

INCREASED ORGANIC SALES TOWARDS PROFITABILITY

PROGRESS WITH RE-COMMERCIALISATION OF US GENERIC PORTFOLIO ACROSS MULTIPLE SITES

MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET

MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GENERIC PHARMACEUTICAL COMPANY, GROWTH & PROFITS

www.idtaus.com.auwww.idtaus.com.au 17

PROGRESS TEMOZOLOMIDE TO COMMERCIAL LAUNCH

Page 18: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

CONTACT US

Dr Paul D R MacLemanMANAGING DIRECTOR

+61 (0) 3 9801 [email protected]

www.idtaus.com.auwww.idtaus.com.au 18

Page 19: IDT Investor Presentation 13Apr16 v3 FINAL...IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only 2% of the

QUESTIONSAND ANSWERS


GAME THEORY. Overview Games capturing strategic decision-making Non-cooperative v/s cooperative games Example of Acquiring a Company Dominant Strategies.

GAME THEORY. Overview Games capturing strategic decision-making Non-cooperative v/s cooperative games Example of Acquiring a Company Dominant Strategies.

IDT Design

IDT Design

RSA - IDT Practice

RSA - IDT Practice

IDT Amendments 29122014

IDT Amendments 29122014

IDT 79R3081 Microprocessor

IDT 79R3081 Microprocessor

Idt Workshop

Idt Workshop

Soc med&idt education_pres_slideshare

Soc med&idt education_pres_slideshare

HRMC Legal & IDT Proposal

HRMC Legal & IDT Proposal

Idt Jc 02 09

Idt Jc 02 09

Idt Shiloh1

Idt Shiloh1

IDT Amendments Padhukas

IDT Amendments Padhukas

IDT Caselaws

IDT Caselaws

Chapter two IDT

Chapter two IDT

NOTICE D’UTILISATION MT-MOTEUR IDT · PDF fileNOTICE D’UTILISATION MT-MOTEUR IDT SUPPORT BANC MOTEUR PEDAGOGIQUE Moteur essence Injection Directe Turbo (IDT)

NOTICE D’UTILISATION MT-MOTEUR IDT · PDF fileNOTICE D’UTILISATION MT-MOTEUR IDT SUPPORT BANC MOTEUR PEDAGOGIQUE Moteur essence Injection Directe Turbo (IDT)

IDT Instalacion Manual3016_USMetric

IDT Instalacion Manual3016_USMetric

IDT Charts

IDT Charts

Idt7201la Idt

Idt7201la Idt

IDT Marketing Sheet

IDT Marketing Sheet

IDT Institute Surat

IDT Institute Surat

IDT Australia Limited ASX Code: IDT Price: $0.250 Business … · Business Summary IDT Australia Limited (IDT) specialises in the development, scale-up and production of potent (HPAPI)

IDT Australia Limited ASX Code: IDT Price: $0.250 Business … · Business Summary IDT Australia Limited (IDT) specialises in the development, scale-up and production of potent (HPAPI)